Platform for assessing molecular testing and treatment outcomes in lung cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a national clinical research platform in Germany to document and analyze data on molecular biomarker testing, treatment, and outcomes for patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). It focuses on collecting uniform data from real-life practice to evaluate the quality of care and develop recommendations for improvement. The study will also assess quality of life and mental health aspects of patients through validated questionnaires, and establish a tissue repository for future research.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients who meet all of the following criteria are eligible for the project:

* Age ≥ 18 years
* Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments

Main project (NSCLC Stage IV):

* Confirmed non-small cell lung cancer (NSCLC)
* Stage IV (UICC8)
* Systemic therapy
* Informed consent no later than four weeks after start of first-line systemic treatment

Satellite NSCLC Stage I-III:

* Confirmed non-small cell lung cancer (NSCLC)
* Informed consent no later than four weeks after start of first anti-tumor treatment (including surgery and radiotherapy) or if first treatment is surgery no longer than 3 months after start of surgery.
* Stage I-III (UICC8)
* Systemic (chemo)therapy and/or radiation therapy and/or surgery

Satellite SCLC

* Confirmed Small cell lung cancer (SCLC)
* Informed consent no later than four weeks after start of first anti-tumor treatment
* Systemic (chemo)therapy and/or radiation therapy and/or surgery

Exclusion Criteria:

none

Where it's running

• Pius-Hospital
  Oldenburg, Germany Recruiting

Study contacts

• Principal investigator: Frank Griesinger, Prof. Dr. — Pius-Hospital Oldenburg
• Study coordinator: Annika Groth
• Email: annika.groth@aio-studien-ggmb.de
• Phone: +49 30-8145344-39

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized treatment for early stage non-small cell lung cancer using blood tests

  This study is testing if a blood test for cancer DNA can help find leftover cancer in people with early stage lung cancer after treatment, and if giving them a specific immunotherapy can help reduce it.

  Recruiting Phase 2 Stanford University · Stanford, California · NCT04585477

• BIO 300 with thoracic radiation for early-stage non-small cell lung cancer and interstitial lung disease

  This trial will test whether adding BIO 300 to thoracic radiation lowers the chance of pneumonitis in people with stage I–II non-small cell lung cancer who also have interstitial lung disease.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07323732

• Cirtuvivint plus irinotecan for relapsed small-cell lung cancer

  This trial will test whether adding cirtuvivint to irinotecan helps people with relapsed small-cell lung cancer respond better and live longer.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT07155200

• Tarlatamab in strong-performance-status small-cell lung cancer

  This trial tests whether tarlatamab can help people with extensive-stage small-cell lung cancer and poor health (ECOG 2) who have already had prior treatment.

  Recruiting at 8 sites Phase 2 AIO-Studien-gGmbH · Berlin and 7 other locations · NCT07803848

• Armored DLL3-SAVVYZ-IL18 CAR T cells for DLL3+ cancers

  Aims to see if DLL3-SAVVYZ-IL18 CAR T cells can be safely given to people with DLL3-positive cancers, including certain small cell lung cancers and other neuroendocrine tumors.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07783477

• Tarlatamab given under the skin vs by IV in extensive-stage small cell lung cancer after platinum therapy

  This trial tests whether subcutaneous tarlatamab works as well as the IV form for people with extensive-stage small cell lung cancer after platinum chemotherapy.

  Recruiting at 9 sites Phase 3 Amgen · Orlando, Florida and 8 other locations · NCT07778316

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.